Thermo Fisher wagers on early cancer diagnostics in $2.6B cash deal for multiple myeloma test maker
Always on the lookout for the next thing to buy, Thermo Fisher Scientific has settled on an oncology diagnostic player for its latest acquisition.
The life sciences conglomerate is shelling out $2.6 billion (£2.25 billion) to acquire The Binding Site Group from a group of private equity investors, integrating a suite of diagnostic assays and instruments for blood cancers and immune system disorders into its specialty diagnostics business.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.